Clinical significance of tumor volume and lymph node involvement assessed by MRI in stage IIB cervical cancer patients treated with concurrent chemoradiation therapy

Dae Woo Lee, YoungTae Kim, Jae-Hoon Kim, Sunghoon Kim, Sang Wun Kim, Eun Ji Nam, Jae Wook Kim

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Objective: The purpose of this study was to evaluate the prognostic significance of tumor volume assessed by pretreatment MRI in stage IIB cervical cancer patients with concurrent chemoradiation therapy. Methods: A retrospective chart review was performed on seventy five patients with cervical cancer who were treated with concurrent weekly cisplatin (40 mg/m 2 ) and radiotherapy between January 2000 and April 2007. Potential prognostic factors were age, chemotherapy numbers, histology, tumor diameter and volume, lymph node (LN) involvement and pretreatment squamous cell carcinoma antigen (SCC-Ag) levels. Results: The median follow-up time was 55 months (range, 8 to 104 months). The median tumor size and volume (range) were 4.5 cm (2 to 10) and 33.1 mL (4.2 to 392.7), respectively. Pelvic LN enlargement rate was 58.7%. Para-aortic LN enlargement rate was 14.7%. Using multivariate analysis, a tumor volume (>33 mL, p=0.025), pelvic LN enlargement (p=0.044) revealed a significantly unfavorable outcome on overall survival. PFS was influenced by tumor histology (p<0.001), pelvic LN enlargement (p=0.015) and pretreatment SCC-Ag levels (p=0.018). We found that 22 (29.3%) patients had recurrences and 14 (18.7%) patients died of disease. The 5-year overall survival rate was 80.6% (standard error, 4.9%) and 5-year PFS rate was 71.3% (standard error, 5.3%). Conclusion: Tumor volume and pelvic LN involvement showed possibility to predict overall survival in patient with stage ÜB cervical cancer. Optimal tumor volume and pelvic LN assessment by pretreatment MRI might be helpful to predict treatment outcome.

Original languageEnglish
Pages (from-to)18-23
Number of pages6
JournalJournal of Gynecologic Oncology
Volume21
Issue number1
DOIs
Publication statusPublished - 2010 Mar 1

Fingerprint

Tumor Burden
Uterine Cervical Neoplasms
Lymph Nodes
Therapeutics
Histology
Survival
Cisplatin
Radiotherapy
Multivariate Analysis
Survival Rate
Recurrence
Drug Therapy
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Obstetrics and Gynaecology

Cite this

@article{db658cee5c5846e4b9a990d5387f3c77,
title = "Clinical significance of tumor volume and lymph node involvement assessed by MRI in stage IIB cervical cancer patients treated with concurrent chemoradiation therapy",
abstract = "Objective: The purpose of this study was to evaluate the prognostic significance of tumor volume assessed by pretreatment MRI in stage IIB cervical cancer patients with concurrent chemoradiation therapy. Methods: A retrospective chart review was performed on seventy five patients with cervical cancer who were treated with concurrent weekly cisplatin (40 mg/m 2 ) and radiotherapy between January 2000 and April 2007. Potential prognostic factors were age, chemotherapy numbers, histology, tumor diameter and volume, lymph node (LN) involvement and pretreatment squamous cell carcinoma antigen (SCC-Ag) levels. Results: The median follow-up time was 55 months (range, 8 to 104 months). The median tumor size and volume (range) were 4.5 cm (2 to 10) and 33.1 mL (4.2 to 392.7), respectively. Pelvic LN enlargement rate was 58.7{\%}. Para-aortic LN enlargement rate was 14.7{\%}. Using multivariate analysis, a tumor volume (>33 mL, p=0.025), pelvic LN enlargement (p=0.044) revealed a significantly unfavorable outcome on overall survival. PFS was influenced by tumor histology (p<0.001), pelvic LN enlargement (p=0.015) and pretreatment SCC-Ag levels (p=0.018). We found that 22 (29.3{\%}) patients had recurrences and 14 (18.7{\%}) patients died of disease. The 5-year overall survival rate was 80.6{\%} (standard error, 4.9{\%}) and 5-year PFS rate was 71.3{\%} (standard error, 5.3{\%}). Conclusion: Tumor volume and pelvic LN involvement showed possibility to predict overall survival in patient with stage {\"U}B cervical cancer. Optimal tumor volume and pelvic LN assessment by pretreatment MRI might be helpful to predict treatment outcome.",
author = "Lee, {Dae Woo} and YoungTae Kim and Jae-Hoon Kim and Sunghoon Kim and Kim, {Sang Wun} and Nam, {Eun Ji} and Kim, {Jae Wook}",
year = "2010",
month = "3",
day = "1",
doi = "10.3802/jgo.2010.21.1.18",
language = "English",
volume = "21",
pages = "18--23",
journal = "Journal of Gynecologic Oncology",
issn = "2005-0380",
publisher = "Korean Society of Gynecologic Oncology and Colposcopy",
number = "1",

}

Clinical significance of tumor volume and lymph node involvement assessed by MRI in stage IIB cervical cancer patients treated with concurrent chemoradiation therapy. / Lee, Dae Woo; Kim, YoungTae; Kim, Jae-Hoon; Kim, Sunghoon; Kim, Sang Wun; Nam, Eun Ji; Kim, Jae Wook.

In: Journal of Gynecologic Oncology, Vol. 21, No. 1, 01.03.2010, p. 18-23.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical significance of tumor volume and lymph node involvement assessed by MRI in stage IIB cervical cancer patients treated with concurrent chemoradiation therapy

AU - Lee, Dae Woo

AU - Kim, YoungTae

AU - Kim, Jae-Hoon

AU - Kim, Sunghoon

AU - Kim, Sang Wun

AU - Nam, Eun Ji

AU - Kim, Jae Wook

PY - 2010/3/1

Y1 - 2010/3/1

N2 - Objective: The purpose of this study was to evaluate the prognostic significance of tumor volume assessed by pretreatment MRI in stage IIB cervical cancer patients with concurrent chemoradiation therapy. Methods: A retrospective chart review was performed on seventy five patients with cervical cancer who were treated with concurrent weekly cisplatin (40 mg/m 2 ) and radiotherapy between January 2000 and April 2007. Potential prognostic factors were age, chemotherapy numbers, histology, tumor diameter and volume, lymph node (LN) involvement and pretreatment squamous cell carcinoma antigen (SCC-Ag) levels. Results: The median follow-up time was 55 months (range, 8 to 104 months). The median tumor size and volume (range) were 4.5 cm (2 to 10) and 33.1 mL (4.2 to 392.7), respectively. Pelvic LN enlargement rate was 58.7%. Para-aortic LN enlargement rate was 14.7%. Using multivariate analysis, a tumor volume (>33 mL, p=0.025), pelvic LN enlargement (p=0.044) revealed a significantly unfavorable outcome on overall survival. PFS was influenced by tumor histology (p<0.001), pelvic LN enlargement (p=0.015) and pretreatment SCC-Ag levels (p=0.018). We found that 22 (29.3%) patients had recurrences and 14 (18.7%) patients died of disease. The 5-year overall survival rate was 80.6% (standard error, 4.9%) and 5-year PFS rate was 71.3% (standard error, 5.3%). Conclusion: Tumor volume and pelvic LN involvement showed possibility to predict overall survival in patient with stage ÜB cervical cancer. Optimal tumor volume and pelvic LN assessment by pretreatment MRI might be helpful to predict treatment outcome.

AB - Objective: The purpose of this study was to evaluate the prognostic significance of tumor volume assessed by pretreatment MRI in stage IIB cervical cancer patients with concurrent chemoradiation therapy. Methods: A retrospective chart review was performed on seventy five patients with cervical cancer who were treated with concurrent weekly cisplatin (40 mg/m 2 ) and radiotherapy between January 2000 and April 2007. Potential prognostic factors were age, chemotherapy numbers, histology, tumor diameter and volume, lymph node (LN) involvement and pretreatment squamous cell carcinoma antigen (SCC-Ag) levels. Results: The median follow-up time was 55 months (range, 8 to 104 months). The median tumor size and volume (range) were 4.5 cm (2 to 10) and 33.1 mL (4.2 to 392.7), respectively. Pelvic LN enlargement rate was 58.7%. Para-aortic LN enlargement rate was 14.7%. Using multivariate analysis, a tumor volume (>33 mL, p=0.025), pelvic LN enlargement (p=0.044) revealed a significantly unfavorable outcome on overall survival. PFS was influenced by tumor histology (p<0.001), pelvic LN enlargement (p=0.015) and pretreatment SCC-Ag levels (p=0.018). We found that 22 (29.3%) patients had recurrences and 14 (18.7%) patients died of disease. The 5-year overall survival rate was 80.6% (standard error, 4.9%) and 5-year PFS rate was 71.3% (standard error, 5.3%). Conclusion: Tumor volume and pelvic LN involvement showed possibility to predict overall survival in patient with stage ÜB cervical cancer. Optimal tumor volume and pelvic LN assessment by pretreatment MRI might be helpful to predict treatment outcome.

UR - http://www.scopus.com/inward/record.url?scp=77953399682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953399682&partnerID=8YFLogxK

U2 - 10.3802/jgo.2010.21.1.18

DO - 10.3802/jgo.2010.21.1.18

M3 - Article

VL - 21

SP - 18

EP - 23

JO - Journal of Gynecologic Oncology

JF - Journal of Gynecologic Oncology

SN - 2005-0380

IS - 1

ER -